文献速递肥胖与代谢综合征

墨西哥肥胖的临床异质性与转变

Clinical Heterogeneity and Transitions of Obesity in Mexico.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

研究基于2006至2022年墨西哥全国健康与营养调查(ENSANUT)数据,分析20758名参与者的肥胖相关共病患病率及15年变化。结果显示肥胖相关共病患病率随时间稳定但随年龄增长而上升,抑郁和活动能力受损在代谢健康肥胖者中也很普遍。肥胖患病率上升和人口老龄化将给人群和卫生系统带来额外负担。

要点

  • 肥胖相关共病在15年间保持稳定,但随年龄增长而增加。
  • 抑郁和活动能力受损在代谢健康肥胖者中也很普遍。
  • 代谢健康肥胖随年龄和BMI增加而可能性降低。

核心结论

  • 墨西哥肥胖相关共病患病率随时间稳定但随年龄增长而上升。
  • 肥胖患病率上升和人口老龄化将给人群和卫生系统带来额外负担。

研究设计与样本

  • 研究收集2006至2022年墨西哥全国健康与营养调查(ENSANUT)数据,共分析20758名参与者。

主要发现

  • 平均体重指数(BMI)在所有年龄组从30.2逐步增至31.0。
  • 医疗维度中最常见的EOSS分期为2期(90.1%),功能维度为1期(75.1%),心理维度为1期(62.9%)。
  • 代谢健康肥胖在男性和女性中随年龄和BMI增加而可能性降低。
  • 肥胖相关共病患病率随年龄增长而增加,但在所有调查轮次间相似。

关键数值与推荐

  • 代谢健康肥胖定义为无糖尿病、血脂异常和高血压。
  • EOSS评估医疗、心理和功能3个维度,分5个递增严重程度分期。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is large variation in the individual risk of developing obesity-associated comorbidities. While obesity is highly prevalent in Mexico, data on the extent and heterogeneity of its associated comorbidities are lacking. OBJECTIVE: We estimated the prevalence of different obesity-associated comorbidities, and how they have changed over 15 years. METHODS: We gathered data from different editions of nationally representative health and nutrition surveys (ENSANUT) from 2006 to 2022. The prevalence of obesity and the coexistence with diabetes, dyslipidemia, hypertension, depression, and impaired mobility, which are outcomes used in the Edmonton Obesity Staging System (EOSS), which assesses 3 dimensions (medical, mental, and functional) across 5 incremental severity stages, by sex and age groups, were estimated across all included surveys. Metabolically healthy obesity (MHO) was defined as the absence of diabetes, dyslipidemia, and hypertension. RESULTS: A total of 20 758 participants were analyzed. Mean body mass index (BMI) increased progressively at all ages from 30.2 to 31.0 across survey rounds. Depression and impaired mobility were highly prevalent even among MHO individuals. While most people with obesity had at least one detectable abnormality, there was large heterogeneity in the presented comorbidities. The most prevalent EOSS categories were stage 2 for the medical dimension (90.1%), and stage 1 for the functional and mental dimensions (75.1% and 62.9%, respectively). The prevalence of obesity-related comorbidities increased with age but was similar across all surveys. In both sexes, MHO was less likely as age and BMI increased. CONCLUSION: The prevalence of obesity comorbidities has been stable over time in Mexico but increases with age. The rising prevalence of obesity and the aging of the population will cause additional burdens to the population and the health system.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Soto-Mota A, Carrillo-Larco RM, Gregg E, et al. Clinical Heterogeneity and Transitions of Obesity in Mexico. J Clin Endocrinol Metab. 2025. PMID: 40067968. doi:10.1210/clinem/dgaf158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。